07.02.2022 09:45
Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), has entered a research agreement with REGENXBIO Inc., a clinical-stage biotechnology company focussed on gene therapy. Athebio will receive an undisclosed upfront payment, research funding fees, and has the potential to receive milestones, as well as royalties on net sales.